The migraine market is expected to experience significant growth, with a reported compound annual growth rate (cagr) of 10.5%. Various reports forecast the market size of migraine drugs and related markets, such as nasal drug delivery and chronic pain drugs, to increase substantially by the mid-2030s. The exact size and scope of the market growth are reported differently across outlets, with some providing specific dollar amounts and timeframes.